Ono Pharmaceutical and Jorna Therapeutics Partner for AI-Driven RNA Editing Therapies
Collaboration Details:
Ono Pharmaceutical has entered a research collaboration with Jorna Therapeutics using Jorna's AI-based RNA editing platform. The partnership aims to develop novel RNA editing therapeutics.
AI Technology:
Jorna's platform utilizes a proprietary protein and RNA generative AI model named SkyEngine, which is based on quantum mechanics-based AI. This model combines large-scale amino acid sequence information and language models to design desired proteins.
Exclusive Rights:
Ono Pharmaceutical has an exclusive option to discover, develop, and commercialize drug candidates worldwide that are generated from RNA editing drug sequences designed by Jorna.
Financial Terms:
The agreement includes an upfront payment to Jorna, research funding, and milestone payments contingent on research progress.
Goals and Benefits:
The partnership aims to accelerate drug development using RNA editing technology to provide new treatment options for patients with unmet medical needs. This collaboration leverages Ono's global resources and Jorna's advanced AI-driven approach.